Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
| Status: | Archived |
|---|---|
| Conditions: | HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | March 2011 |
| End Date: | August 2012 |
A Randomized Controlled Pilot Trial Comparing Continued Antiretroviral Therapy With Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) With Switch to Tenofovir/Emtricitabine/Raltegravir (TDF/FTC/RAL) on Changes in Endothelial Function and Markers of Bone Metabolism
Efavirenz, a commonly used HIV medication, may cause worsening vascular function and bone
problems. The purpose of this study is to determine if switching efavirenz to raltegravir, a
newer HIV medication, will improve vascular function and tests of bone health.
Cardiovascular disease (CVD) is an increasingly important comorbidity in HIV-infected
patients. Our preliminary data suggests that efavirenz may worsen endothelial function,
which in turn may increase the risk for future CVD events. Efavirenz has also been linked to
lower vitamin D levels, which may in turn result in increased bone fragility. Raltegravir is
not known to affect either endothelial function or vitamin D levels. Therefore, switching
efavirenz to raltegravir in patients with suppressed HIV viremia may lead to improved
outcomes.
We found this trial at
1
site
Click here to add this to my saved trials
